Cedars-Sinai/JHU study: Three-drug combo prevents pancreatic cancer metastasis

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Earlier this year, FDA announced that it would be initiating a voucher program aimed at accelerating review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, June 20, 2025).

October 24, 2025

By Claire Marie Porter

In Brief

GammaTile delivers superior tumor control vs. standard-of-care for newly diagnosed operable brain metastases

GammaTile showed superiority in the primary endpoint of the study. Patients who received GammaTile lived longer without tumor regrowth, reducing the risk of either tumor recurrence or death by 50% reduction compared to standard of care, according to interim results from the ROADS clinical trial, which evaluated GammaTile versus standard of care in patients with operable, newly diagnosed brain metastases.

October 24, 2025

In Brief

Enzalutamide drug combination cuts risk of death in advanced prostate cancer, Cedars-Sinai-led study shows

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

October 24, 2025

Clinical Roundup

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.

October 17, 2025

Vol.51 No.38

KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill

In 1988, Frank McCormick learned with the rest of the field that more than 90% of patients with pancreatic cancer have a mutation in the Kirsten rat sarcoma viral gene.

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

UT Southwestern Medical Center researchers have identified two distinct populations of cells known as antigen-presenting cancer-associated fibroblasts that appear to support the survival and growth of malignant tumors.

October 10, 2025

Vol.51 No.37

Cedars-Sinai/JHU study: Three-drug combo prevents pancreatic cancer metastasis

YOU MAY BE INTERESTED IN

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

GammaTile delivers superior tumor control vs. standard-of-care for newly diagnosed operable brain metastases

Enzalutamide drug combination cuts risk of death in advanced prostate cancer, Cedars-Sinai-led study shows

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

Renew today!

Subscriber content

Never miss an issue!

Login